Experimental research

MAHOROBA™: Tacrolimus eluting coronary stent

EuroInterv.2007;3:149-153.

Shuzou Tanimoto1, MD; Willem J. van der Giessen1,2, MD, PhD; Heleen M. van Beusekom2, PhD; Oana Sorop2, PhD; Neville Kukreja1, MA, MRCP; Kohei Fukaya3; Takuji Nishide3; Ryohji Nakano3; Hiromi Maeda3; Patrick W. Serruys1*, MD, PhD

1. Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 2. Department of Experimental Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 3. Kaneka Corporation, Osaka, Japan

Description

Kaneka’s coronary stent, MAHOROBA™, is a new drug eluting stent (DES), which combines a thin, flexible cobalt-chromium (CoCr) metal stent platform coated with a biodegradable polymer including the pharmaceutical agent tacrolimus. The device has been designed and developed to inhibit the growth of neointimal hyperplasia and avoid interference with the vascular healing response.

History

The advent of DES has revolutionised the practice of interventional cardiology by inhibiting the development of neointimal hyperplasia and thereby reducing the rates of restenosis and repeat revascularisation as compared to bare metal stents (BMS)1-4. After the first approval of ...

Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Share on Facebook Share on Twitter Share on Linkedin